ConvaTec Group (LON:CTEC) Shares Down 1.3% – Should You Sell?

Shares of ConvaTec Group PLC (LON:CTEC) were down 1.3% on Tuesday . The stock traded as low as GBX 238.60 and last traded at GBX 238.60. Approximately 3,496,931 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 18,504,021 shares. The stock had previously closed at GBX 241.80.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CTEC shares. Peel Hunt restated an “add” rating and set a GBX 270 target price on shares of ConvaTec Group in a research report on Thursday, November 13th. UBS Group reissued a “buy” rating and set a GBX 375 price objective on shares of ConvaTec Group in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 318.67.

ConvaTec Group Trading Down 1.3%

The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. The stock has a market cap of £4.67 billion, a P/E ratio of 22.51, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The business’s fifty day simple moving average is GBX 237.72 and its 200 day simple moving average is GBX 244.36.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.